| DC23635 |
YM 758 |
A novel potent "funny" If current channel (If channel) inhibitor that inhibits rOct1- and hOCT1-mediated [3H]MPP uptake with IC50 of 23.8 and 40.5 uM, respectively. |
|
| DC23542 |
LY3031207 |
A novel potent (IC50=910 ng/mL), highly selective microsomal prostaglandin E synthase 1 inhibitor (mPGES-1) for treatment of undisclosed indications.. |
|
| DC11994 |
ZQ-16 |
A novel potent and selective agonist of GPR84 that induces calcium response with EC50 of 0.213 uM. |
|
| DC23841 |
EW-7195
Featured
|
A novel potent and selective TGF-βRI (ALK5) inhibitor with IC50 of 4.83 nM, dispalys >300-fold selectivity over p38α. |
|
| DC22734 |
UR-1102 |
A novel potent and selective, orally active URAT1 inhibitor with Ki of 57 nM, 130 and 42-fold selectivity over OAT1 and OAT3, respectively. |
|
| DC20826 |
BPR1K653 hydrochloride |
A novel potent Aurora kinase inhibitor that inhibits Aurora-A and Aurora-B with IC50 of 24 nM and 45 nM, respectively. |
|
| DC21048 |
GIV3727 |
A novel potent bitter receptor (TAS2Rs) antagonist that inhibits activation of hTAS2R31 by saccharin and acesulfame K with IC50 of 6.4 and 7.9 uM respectively. |
|
| DC20534 |
Revosimeline |
A novel potent cannabinoid receptor agonist.. |
|
| DC20435 |
Leucettine L41 |
A novel potent cdc2-like kinase (CLKs) and DYRKs inhibitor with IC50 of 40, 35 and 15 nM for DYRK1A, DYRK2 and CLK1, respectively. |
|
| DC21453 |
Riviciclib |
A novel potent CDK inhibitor with IC50 of 79 nM, 63 nM and 20 nM for Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, respectively. |
|
| DC22743 |
OSSK-674842 |
A novel potent CFTR potentiator that blocks hCFTR with apparent Kd of 71.3 uM. |
|
| DC22739 |
OSSK-630513 |
A novel potent CFTR potentiator with Kd of 31.7 nM. |
|
| DC21855 |
ZINC 39395747
Featured
|
ZINC 39395747 is a novel potent derivative of propylthiouracil that functions as a cell-active inhibitor of cytochrome b5 reductase 3 (CYB5R3) with IC50 of 9.14 uM. |
|
| DC11600 |
D211 |
A novel potent DNA-intercalating payload dimer (PBD dimer) payload for antibody-drug conjugates (ADCs). |
|
| DC20437 |
Linzagolix |
A novel potent gonadotrophin releasing hormone (GnRH) antagonist.. |
|
| DC20482 |
Opigolix |
A novel potent gonadotrophin releasing hormone (GnRH) antagonist.. |
|
| DC22861 |
CRT-0105950 |
A novel potent LIMK inhibitor with IC50 of 0.3 nM and 1 nM for LIMK1 and LIMK2, respectively. |
|
| DC22862 |
CRT-0105446 |
A novel potent LIMK inhibitor with IC50 of 8 nM and 32 nM for LIMK1 and LIMK2, respectively. |
|
| DC11622 |
MAP3K14-IN-173 |
A novel potent MAP3K14 kinase inhibitor with IC50 of 1.8 nM (NIK autophosphorylation). |
|
| DC11515 |
Azeloprazole |
A novel potent proton pump inhibitor that irreversibly inhibits H+,K+-ATPase activity with IC50 of 0.28 uM. |
|
| DC23393 |
BETi-211 |
A novel potent small-molecule BET bromodomain (BRD) inhibitor that binds to BET proteins with Ki values of <1 nM. |
|
| DC11995 |
BI 703704 |
A novel potent soluble guanylate cyclase (sGC) activator. |
|
| DC11880 |
TH1834 |
A novel potent specific histone acetyltransferaseTip60 inhibitor. |
|
| DC11881 |
TH1834 dihydrochloride |
A novel potent specific histone acetyltransferaseTip60 inhibitor. |
|
| DC22798 |
ADA-07 |
A novel potent TOPK inhibitor that effectively suppresses SUV-induced activation of MAPKs signal transduction resulting in reduced SUV-induced skin carcinogenesis. |
|
| DC11603 |
SR-19871 |
A novel potent ULK1 inhibitor with IC50 of 11 nM.. |
|
| DC11693 |
AJS1669 sodium |
A novel potent, allosteric, orally available muscle glycogen synthase 1 (GYS1) activator with EC50 of 5.2 uM. |
|
| DC11692 |
AJS1669 |
A novel potent, allosteric, orally available muscle glycogen synthase 1 (GYS1) activator with EC50 of 5.2 uM. |
|
| DC21354 |
MT47-100
Featured
|
MT47-100 is a novel compound that exhibits a unique dual functionality as both an allosteric activator and inhibitor of AMP-activated protein kinase (AMPK) complexes, depending on the isoform present. Specifically, MT47-100 acts as a direct activator of AMPK complexes containing the β1 isoform and as a direct inhibitor of AMPK complexes containing the β2 isoform. This isoform-specific modulation of AMPK activity makes MT47-100 a potentially valuable tool for studying the distinct physiological roles of β1- and β2-containing AMPK complexes, as well as a candidate for therapeutic applications targeting AMPK-related pathways. |
|
| DC23525 |
AAT-008 |
A novel potent, and selective prostaglandin EP4 receptor antagonist with binding IC50 of 2.4 nM. |
|
